Prokarium Expands R&D Capabilities with London Biofoundry to Deepen Microbial Immunotherapy Pipeline
26.1.2022 12:00:00 EET | Business Wire | Press release
Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, has entered into an agreement, through Imperial Projects, to work with independent researchers from Imperial College London to develop Prokarium’s next-generation therapeutic candidates, engineered to deliver payloads within the tumor microenvironment.
“Prokarium is designing the perfect bacteria to be the next cancer immunotherapy, and we believe leveraging Salmonella’s unique biology will allow us to combine a powerful innate approach with a tailored adaptive response,” said Kristen Albright, PharmD, Chief Executive Officer of Prokarium. “This agreement will significantly expand our R&D capabilities and will further deepen our immunotherapy pipeline.”
This new multi-year agreement builds on work between Prokarium and London Biofoundry that was initiated in 2020 and will further expand Prokarium’s operations. The team from Imperial’s and SynbiCITE’s London Biofoundry specializes in the design, engineering and functional characterisation of synthetic DNA and organisms.
“Prokarium has uniquely positioned their Salmonella platform as an innovative immunotherapy approach for the treatment of solid tumors, and we are excited to support their efforts in pioneering the cancer treatment paradigm shift from synthetic chemistry to synthetic biology,” said Marko Storch, PhD, Head of Synthetic Biology and Automation. “At the London Biofoundry, we developed a cutting-edge SynBio stack and the expertise to collaborate with researchers and biotechs to advance their R&D. We are thrilled to leverage our leading research capabilities to support the development of Prokarium’s new class of medicines in oncology.”
About the London Biofoundry
The London Biofoundry provides a suite of state-of-the-art robotic equipment and expertise supporting automated end-to-end design, construction, and validation of large gene constructs and biological systems. For more information visit www.londonbiofoundry.org
About Imperial College London
Imperial College London is one of the world's leading universities. The College's 20,000 students and 8,000 staff are working to solve the biggest challenges in science, medicine, engineering and business. Reuters named the College as the UK's most innovative university because of its exceptional entrepreneurial culture and ties to industry. For more information visit http://www.imperial.ac.uk/
About Prokarium
Prokarium is a biopharmaceutical company pioneering the field of microbial immunotherapy. Our pipeline is designed to unlock the next level of immuno-oncology by building on the most recent advances in cancer immunology. Prokarium’s lead program is focused on transforming the treatment paradigm in bladder cancer by orchestrating immune-driven, long-lasting antitumor effects. Prokarium is based in London, UK. For further information, visit https://www.prokarium.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220126005069/en/
Contact information
Contacts
For Prokarium
Kristen Albright
Chief Executive Officer
kristen.albright@prokarium.com
www.prokarium.com
For media
MacDougall Advisors
Matthew Corcoran
+1 781-235-3060
prokarium@macdougall.bio
www.macdougall.bio
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mobix Labs Signs Definitive Agreement to Acquire Vision Aerial, Accelerating Global Drone Platform for National Security and Aerial Intelligence24.7.2026 14:00:00 EEST | Press release
Mobix Labs, Inc. (Nasdaq: MOBX) today announced that it has signed a definitive agreement to acquire Vision Aerial, Inc., a U.S.-based designer and manufacturer of American-built, National Defense Authorization Act (NDAA)-compliant unmanned aerial systems. The definitive agreement moves the transaction beyond the previously announced letter of intent and represents a major step toward closing an acquisition that would expand Mobix Labs into one of the world’s most important technology growth markets: secure drones, autonomous aerial systems and aerial intelligence for national security, critical infrastructure, energy, public safety, industrial inspection and government operations. Vision Aerial’s customers and end-users include the U.S. Air Force, U.S. Navy, government agencies, energy and utility operators, research institutions and other organizations requiring performance, reliability and trusted supply chains. Its drones support national security and public-safety operations, sear
Enhertu ® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer24.7.2026 14:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) in combination with pertuzumab has been recommended for approval in the European Union (EU) for the first-line treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from theDESTINY-Breast09 phase 3 trialpresented at the 2025 American Society of Clinical Oncology Annual Meeting and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DESTI
SLB Announces Second-Quarter 2026 Results24.7.2026 13:50:00 EEST | Press release
SLB (NYSE: SLB) today announced results for the second-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722694386/en/ The exterior of the SLB headquarters in Houston, Texas. Second-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeJun. 30, 2026Mar. 31, 2026Jun. 30, 2025SequentialYear-on-yearRevenue $8,972 $8,721 $8,546 3% 5% Income before taxes - GAAP basis $1,018 $956 $1,285 6% -21% Income before taxes margin - GAAP basis 11.3% 11.0% 15.0% 38 bps -369 bps Net income attributable to SLB - GAAP basis $786 $752 $1,014 5% -22% Diluted EPS - GAAP basis $0.52 $0.50 $0.74 4% -30% Adjusted EBITDA* $1,899 $1,773 $2,051 7% -7% Adjusted EBITDA margin* 21.2% 20.3% 24.0% 83 bps -284 bps Pretax segment operating income* $1,404 $1,321 $1,584 6% -11% Pretax segment operating margin* 15.6% 15.2% 18.5% 49 bps -289 bps Net income attributable to SLB, excluding charges & credits* $833 $783 $1,0
NIQ Expands GenAI Capabilities Across gfknewron, Turning Trusted Intelligence into Decisions Faster24.7.2026 13:30:00 EEST | Press release
NIQ (NYSE: NIQ), a leader in consumer intelligence, today announced the expansion of AI-powered Smart Insights across its gfknewron® platform. By bringing together markets and categories into a single view, gfknewron enables businesses to transform complex market, consumer and supply chain data into clear, actionable intelligence quickly. The latest enhancements help users identify trends, opportunities and performance drivers more quickly, reducing the time required to analyze large datasets and accelerating confident decision-making across teams. As brands and retailers face growing pressure to respond quickly to changing consumer behavior and market dynamics, the ability to unlock meaningful insights from increasingly rich datasets has become a significant competitive advantage. As AI is only as effective as the intelligence behind it, Smart Insights helps businesses realize the full value of NIQ's trusted market intelligence by automatically surfacing the trends, opportunities and
Thales to Strengthen Romania’s Airspace Protection With Twelve Ground Master 200 MM/A Radars24.7.2026 11:05:00 EEST | Press release
In a context of growing collaboration between European nations to bolster collective security, the Romanian General Directorate for Armaments has just signed a landmark agreement with France’s Direction Générale de l’Armement (DGA) to acquire twelve Thales Ground Master 200 Multi-Mission All-in-one (GM200 MM/A) radars. This government-to-government agreement, funded under the European Union’s SAFE programme, underlines the high level of partnership between France and Romania. The first delivery is expected in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260724603527/en/ The Romanian General Directorate for Armaments and the French Direction Générale de l’Armement (DGA – the French defence procurement agency) have signed an agreement to supply twelve Thales GM200 Multi-Mission All-in-one (GM200MM/A) radars to protect the Romanian airspace. The GM200 MM/A is a combat-proven medium-range 4D AESA radar, already deployed
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom